Roche, Regeneron link up to develop Covid-19 antibody cocktail | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Monday
September 25, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
MONDAY, SEPTEMBER 25, 2023
Roche, Regeneron link up to develop Covid-19 antibody cocktail

Coronavirus chronicle

Reuters
19 August, 2020, 05:40 pm
Last modified: 19 August, 2020, 05:46 pm

Related News

  • Roche keen on serving more cancer and rare disease patients in Bangladesh  
  • Roche develops test kits to detect monkeypox virus
  • India approves Roche/Regeneron antibody cocktail to treat Covid-19
  • Roche looking for new place to test Covid-19 pill after cases plummet in UK
  • Eli Lilly's antibody combination receives FDA emergency use authorization for Covid-19

Roche, Regeneron link up to develop Covid-19 antibody cocktail

Roche has one of the world's largest antibody production operations, including US facilities in San Francisco, and will boost overall capacity for REGN-COV2 by at least three and a half times, a feat Regeneron would have been hard pressed to accomplish going it alone

Reuters
19 August, 2020, 05:40 pm
Last modified: 19 August, 2020, 05:46 pm
The logo of Swiss pharmaceutical company Roche is seen outside the Shanghai Roche Pharmaceutical Co. Ltd. headquarters in Shanghai May 22, 2014/ Reuters
The logo of Swiss pharmaceutical company Roche is seen outside the Shanghai Roche Pharmaceutical Co. Ltd. headquarters in Shanghai May 22, 2014/ Reuters

Roche is adding its manufacturing muscle and global development expertise to Regeneron's bid to create an antibody cocktail for Covid-19 that the Swiss and US companies hope can be used to slow the pandemic.

Regeneron, which expects data from REGN-COV2 in humans next month after it prevented and treated the disease in rhesus macaques and hamsters, would handle US sales and Roche worldwide distribution should it win approval, the companies said on Wednesday.

Roche has one of the world's largest antibody production operations, including US facilities in San Francisco, and will boost overall capacity for REGN-COV2 by at least three and a half times, a feat Regeneron would have been hard pressed to accomplish going it alone.

"This major collaboration with Roche provides important scale and global expertise to bring REGN-COV2 to many more patients in the United States and around the globe," Regeneron Chief Executive Leonard Schleifer said.

Roche's move to join up comes after its own drug, Actemra, failed in a trial against Covid-19.

The companies will fund and run ongoing late-stage Phase 3 prevention and earlier-stage Phase 1 healthy volunteers safety studies, as well as additional studies to evaluate REGN-COV2 in treating or preventing Covid-19.

The medicine combines one Regeneron-made antibody and a second antibody isolated from humans who recovered from Covid-19.

The combination is designed to bind to the spike protein used by the new coronavirus to gain access to human cells, limiting its ability to escape.

Zuercher Kantonalbank analyst Michael Nawrath said he expects REGN-COV2 to win regulators' blessings.

"With big biotech facilities at its Genentech unit, Roche can quickly scale up production capacity," Nawrath wrote. "Global supplies can be guaranteed, something Regeneron couldn't have done by itself."

Roche shares were up 1.1 percent at 1056 GMT.

Top News

Covid-19 Antibody Test / Roche

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • No scope to settle trade in Russian ruble: Cenbank
    No scope to settle trade in Russian ruble: Cenbank
  • Jamuna rail bridge: East part progressing but west lags behind
    Jamuna rail bridge: East part progressing but west lags behind
  • File Photo: UNB
    Elevated Expressway: Over Tk5 crore toll collected in first 3 weeks

MOST VIEWED

  • Representational image. Photo: Pixabay
    Train runs over 3 children at Mohakhali crossing
  • Photo: Courtesy
    BPL 2024: Updated squads of all 7 teams
  • Russian 100-rouble banknotes are placed on a cashier's desk at a supermarket in the Siberian town of Tara in the Omsk region, Russia, December 14, 2021. Picture taken December 14, 2021. REUTERS/Alexey Malgavko
    Bangladesh among over 30 countries approved to trade in rouble: Russian Embassy
  • Photo: Collected
    BR rolling out railway luggage van service Sunday
  • British American Tobacco BD to build Tk150cr bonded warehouse
    British American Tobacco BD to build Tk150cr bonded warehouse
  • Muhammad Saeedul Alam and Shabab Shahriar Khan. Sketch: TBS
    Biniyog.io: How an investment platform is bridging the SME funding gap

Related News

  • Roche keen on serving more cancer and rare disease patients in Bangladesh  
  • Roche develops test kits to detect monkeypox virus
  • India approves Roche/Regeneron antibody cocktail to treat Covid-19
  • Roche looking for new place to test Covid-19 pill after cases plummet in UK
  • Eli Lilly's antibody combination receives FDA emergency use authorization for Covid-19

Features

Photo: Bloomberg

New India-EU trade route: Bringing the Gulf states closer?

3h | Panorama
Daahuk has trained over 1,000 people for different livelihood options and facilitated the employment of around 500 villagers. Photo: Courtesy

Daahuk: A for-profit approach to development

3h | Panorama
Jhantu Majhi poses for a photo with the paddle on his hand in Ratargul Swamp Forest. Photo: Md Tajul Islam

The children of Ratargul swamp go to school, sing songs and sail

20h | Features
The founders of the salon, Evana Rahman (left), Kazi Faraz Abir (top left), Pinky Peya (right), and Mudassir Ahmed Anik (top right). Photo: Courtesy

Studio Ombre: Where influencers make you 'instagrammable'

23h | Mode

More Videos from TBS

Potatoes are being sold at Tk 36 in Munshiganj under the initiative of the DC

Potatoes are being sold at Tk 36 in Munshiganj under the initiative of the DC

54m | TBS Stories
Agreement signed to export rice bran oil to Japan

Agreement signed to export rice bran oil to Japan

15h | TBS Today
Is 'Mankading' really ruining the 'Spirit of Cricket'?

Is 'Mankading' really ruining the 'Spirit of Cricket'?

14h | TBS SPORTS
Ukraine in the face of a long war: no way without changing strategy!

Ukraine in the face of a long war: no way without changing strategy!

16h | TBS World
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]